Holen Sie sich die Stockscreener-App
1.06
8.62%
-0.10
Vorhandelsmarkt:
1.06
Schlusskurs vom Vortag:
$1.16
Offen:
$1.11
24-Stunden-Volumen:
241.10K
Relative Volume:
0.12
Marktkapitalisierung:
$5.81M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-8.72M
KGV:
-0.1932
EPS:
-5.4871
Netto-Cashflow:
$-5.47M
1W Leistung:
-0.93%
1M Leistung:
-13.11%
6M Leistung:
-33.75%
1J Leistung:
-65.25%
1-Tages-Spanne:
$1.0545
$1.135
1-Wochen-Bereich:
$1.03
$1.21
52-Wochen-Spanne:
$0.7449
$3.61
Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile
Firmenname
Galmed Pharmaceuticals Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie GLMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GLMD
Galmed Pharmaceuticals Ltd
|
1.06 | 6.36M | 0 | -8.72M | -5.47M | -5.4871 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-05-22 | Herabstufung | B. Riley FBR | Buy → Neutral |
| 2020-02-04 | Eingeleitet | Craig Hallum | Buy |
| 2020-01-30 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-12-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Buy |
| 2018-08-02 | Bestätigt | Maxim Group | Buy |
| 2018-07-13 | Eingeleitet | Stifel | Buy |
| 2018-07-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-06-12 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2018-02-14 | Herabstufung | Maxim Group | Buy → Hold |
| 2018-02-12 | Bestätigt | H.C. Wainwright | Buy |
| 2017-11-15 | Eingeleitet | ROTH Capital | Buy |
| 2017-08-08 | Bestätigt | H.C. Wainwright | Buy |
| 2017-07-31 | Bestätigt | Maxim Group | Buy |
| 2016-08-01 | Bestätigt | Maxim Group | Buy |
| 2016-07-06 | Fortgesetzt | ROTH Capital | Buy |
| 2016-03-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2015-06-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-05-06 | Eingeleitet | Sun Trust Rbsn Humphrey | Buy |
Alle ansehen
Galmed Pharmaceuticals Ltd Aktie (GLMD) Neueste Nachrichten
Galmed Pharmaceuticals’ Aramchol Abstract Accepted for HEP-DART 2025 Presentation - TipRanks
Galmed to present data on Aramchol’s potential in liver cancer By Investing.com - Investing.com Australia
Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting - Yahoo Finance
Galmed receives patent for combination therapy in South Korea By Investing.com - Investing.com Nigeria
Can Galmed Pharmaceuticals Ltd. (GPH) stock surprise with quarterly resultsBuy Signal & Weekly Breakout Watchlists - Newser
Galmed Announces Grant of New Use Patents for the Combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra for Mash - marketscreener.com
Galmed stock rises after patent grant for MASH combo therapy By Investing.com - Investing.com Nigeria
Galmed stock rises after patent grant for MASH combo therapy - Investing.com
Galmed receives patent for combination therapy in South Korea - Investing.com
Galmed Pharmaceuticals Secures New Patent for Aramchol Combination Therapy - TipRanks
Galmed announces grant of new use patents for the combination of Aramchol and Madrigal Pharmaceuticals - marketscreener.com
Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH - WV News
Can Galmed Pharmaceuticals Ltd. (GPH) stock sustain free cash flowQuarterly Trade Review & Accurate Trade Setup Notifications - Newser
Galmed Pharmaceuticals (NASDAQ:GLMD) Stock Passes Below 200-Day Moving Average – Should You Sell? - Defense World
Is Galmed Pharmaceuticals Ltd. (GPH) stock supported by strong fundamentals2025 EndofYear Setup & Risk Managed Investment Signals - Newser
Is Galmed Pharmaceuticals Ltd. (GPH) stock good for long term investing - Newser
Can Galmed Pharmaceuticals Ltd. (GPH) stock attract ESG investmentsTrade Volume Summary & High Accuracy Investment Signals - Newser
Galmed Pharmaceuticals Shares Edge Higher Following CEO’s Positive Update - MSN
Galmed Pharmaceuticals Expands Aramchol’s Clinical Applications and Strengthens Financial Position - MSN
Is Galmed Pharmaceuticals Ltd. (GPH) stock positioned for digital growth era2025 Trading Volume Trends & Real-Time Buy Signal Notifications - Newser
Galmed reports $19.2 million cash position, advances Aramchol programs By Investing.com - Investing.com Nigeria
Galmed Pharmaceuticals stock rises on CEO’s optimistic outlook By Investing.com - Investing.com Nigeria
Galmed Pharmaceuticals stock rises on CEO’s optimistic outlook - Investing.com
Galmed reports $19.2 million cash position, advances Aramchol programs - Investing.com
Galmed Issues CEO Letter to Shareholders - Sahm
Galmed Pharmaceuticals (GLMD) Stock Analysis Report | Financials & Insights - Benzinga
What drives Galmed Pharmaceuticals Ltd stock priceEx-Dividend Date Alerts & Fast Growing Portfolio Trading - earlytimes.in
Is Galmed Pharmaceuticals Ltd. stock a defensive play in 2025Quarterly Trade Report & Consistent Profit Trading Strategies - BỘ NỘI VỤ
Energy Moves: How interest rate cuts could boost Galmed Pharmaceuticals Ltd. stockJuly 2025 Institutional & High Accuracy Trade Signal Alerts - moha.gov.vn
EV Market: How Galmed Pharmaceuticals Ltd. stock compares to growth peersJuly 2025 Action & Fast Gaining Stock Reports - BỘ NỘI VỤ
Galmed Pharmaceuticals Ltd (GLMD) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Setenews
Galmed Pharmaceuticals: Q3 Earnings Snapshot - Stamford Advocate
How Galmed Pharmaceuticals Ltd. stock compares to growth peersJuly 2025 Fed Impact & Capital Protection Trade Alerts - BỘ NỘI VỤ
Galmed Pharmaceuticals Reports Q3 2025 Financials and Research Breakthroughs - TipRanks
Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update - PR Newswire
Will Galmed Pharmaceuticals Ltd. stock outperform tech sector in 2025July 2025 Opening Moves & AI Forecast for Swing Trade Picks - BỘ NỘI VỤ
MSN Money - MSN
Galmed Pharmaceuticals Ltd. (GLMD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Key metrics from Galmed Pharmaceuticals Ltd.’s quarterly dataJuly 2025 Sector Moves & Verified Stock Trade Ideas - newser.com
Can swing trading help recover from Galmed Pharmaceuticals Ltd. lossesTrade Ideas & Daily Profit Maximizing Tips - newser.com
Is Galmed Pharmaceuticals Ltd. (GPH) stock resilient in recession scenarios - newser.com
Is Galmed Pharmaceuticals Ltd. (GPH) stock suitable for passive index fundsWeekly Trading Summary & Verified Momentum Watchlists - newser.com
Why Galmed Pharmaceuticals Ltd. stock attracts global investorsWeekly Gains Summary & Detailed Earnings Play Strategies - newser.com
Galmed Pharmaceuticals Reveals Promising Results in Oncology Drug Combination Study - MSN
How buyback programs support Galmed Pharmaceuticals Ltd. (GPH) stock2025 Macro Impact & AI Enhanced Trading Alerts - newser.com
Finanzdaten der Galmed Pharmaceuticals Ltd-Aktie (GLMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):